Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 35 | 2023 | 2951 | 3.380 |
Why?
|
Hematopoietic Stem Cell Transplantation | 38 | 2023 | 5425 | 2.690 |
Why?
|
Bone Marrow Transplantation | 23 | 2023 | 2763 | 2.290 |
Why?
|
Anemia, Sickle Cell | 15 | 2022 | 1017 | 1.610 |
Why?
|
Transplantation Conditioning | 18 | 2023 | 1597 | 1.540 |
Why?
|
HLA Antigens | 11 | 2019 | 1382 | 1.010 |
Why?
|
Leukemia, Myeloid, Acute | 13 | 2022 | 3497 | 0.940 |
Why?
|
Hematologic Diseases | 4 | 2017 | 498 | 0.900 |
Why?
|
Pancytopenia | 2 | 2023 | 104 | 0.900 |
Why?
|
Leukemia | 6 | 2017 | 1507 | 0.750 |
Why?
|
Erythrocyte Transfusion | 4 | 2016 | 565 | 0.740 |
Why?
|
Histocompatibility Testing | 10 | 2023 | 742 | 0.730 |
Why?
|
Histocompatibility | 4 | 2013 | 330 | 0.710 |
Why?
|
Vidarabine | 2 | 2015 | 345 | 0.680 |
Why?
|
Isoantibodies | 5 | 2019 | 680 | 0.680 |
Why?
|
Siblings | 8 | 2017 | 854 | 0.650 |
Why?
|
Cord Blood Stem Cell Transplantation | 3 | 2015 | 314 | 0.580 |
Why?
|
Busulfan | 3 | 2015 | 262 | 0.580 |
Why?
|
Virus Activation | 2 | 2015 | 319 | 0.540 |
Why?
|
H-Y Antigen | 1 | 2015 | 45 | 0.530 |
Why?
|
Antilymphocyte Serum | 3 | 2015 | 491 | 0.520 |
Why?
|
Anemia, Aplastic | 3 | 2015 | 226 | 0.510 |
Why?
|
Leukemia, Biphenotypic, Acute | 3 | 2019 | 35 | 0.490 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2015 | 1366 | 0.490 |
Why?
|
Cytomegalovirus Infections | 3 | 2016 | 817 | 0.480 |
Why?
|
Transplantation, Homologous | 19 | 2022 | 4771 | 0.470 |
Why?
|
Tissue Donors | 6 | 2021 | 2205 | 0.460 |
Why?
|
Rifamycins | 1 | 2013 | 25 | 0.460 |
Why?
|
Viremia | 1 | 2016 | 735 | 0.450 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 4 | 2012 | 272 | 0.450 |
Why?
|
Cytomegalovirus | 2 | 2015 | 730 | 0.450 |
Why?
|
Graft Rejection | 7 | 2014 | 4393 | 0.450 |
Why?
|
Lymphocyte Depletion | 1 | 2015 | 608 | 0.450 |
Why?
|
Child | 46 | 2023 | 77478 | 0.390 |
Why?
|
Cyclophosphamide | 3 | 2015 | 2236 | 0.390 |
Why?
|
Acute Disease | 11 | 2021 | 7141 | 0.370 |
Why?
|
Adolescent | 43 | 2021 | 85649 | 0.360 |
Why?
|
Bacteremia | 1 | 2016 | 962 | 0.350 |
Why?
|
Hematologic Neoplasms | 4 | 2023 | 1820 | 0.350 |
Why?
|
Child, Preschool | 32 | 2019 | 40955 | 0.350 |
Why?
|
Immunophenotyping | 5 | 2019 | 1866 | 0.340 |
Why?
|
Infant | 23 | 2019 | 35070 | 0.290 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3770 | 0.280 |
Why?
|
Cross-Priming | 1 | 2005 | 82 | 0.260 |
Why?
|
Young Adult | 24 | 2021 | 56350 | 0.250 |
Why?
|
Diagnostic Tests, Routine | 1 | 2010 | 783 | 0.240 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2005 | 298 | 0.240 |
Why?
|
Decision Making | 1 | 2018 | 3869 | 0.240 |
Why?
|
Immunity | 1 | 2010 | 1011 | 0.240 |
Why?
|
Thalassemia | 1 | 2005 | 273 | 0.240 |
Why?
|
Immunosuppressive Agents | 8 | 2023 | 4147 | 0.240 |
Why?
|
Living Donors | 5 | 2014 | 618 | 0.220 |
Why?
|
Immunity, Innate | 1 | 2015 | 2956 | 0.220 |
Why?
|
Myeloablative Agonists | 5 | 2014 | 218 | 0.210 |
Why?
|
Glomerular Filtration Rate | 1 | 2010 | 2167 | 0.210 |
Why?
|
Graft Survival | 8 | 2015 | 3733 | 0.200 |
Why?
|
Disease-Free Survival | 12 | 2019 | 6891 | 0.200 |
Why?
|
Humans | 71 | 2023 | 742088 | 0.200 |
Why?
|
Cause of Death | 2 | 2013 | 3571 | 0.200 |
Why?
|
Myelodysplastic Syndromes | 3 | 2022 | 1351 | 0.200 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7276 | 0.190 |
Why?
|
Immunization | 1 | 2005 | 1255 | 0.190 |
Why?
|
Male | 45 | 2021 | 349538 | 0.180 |
Why?
|
Female | 47 | 2021 | 379592 | 0.180 |
Why?
|
Antibodies | 2 | 2018 | 2459 | 0.170 |
Why?
|
Remission Induction | 7 | 2014 | 2384 | 0.170 |
Why?
|
T-Lymphocytes | 2 | 2013 | 10163 | 0.160 |
Why?
|
Whole-Body Irradiation | 5 | 2014 | 449 | 0.160 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2014 | 1515 | 0.160 |
Why?
|
Hemostatics | 1 | 2001 | 229 | 0.160 |
Why?
|
Thrombophilia | 1 | 2001 | 305 | 0.160 |
Why?
|
Survival Analysis | 9 | 2017 | 10248 | 0.160 |
Why?
|
Adult | 31 | 2021 | 213712 | 0.150 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 569 | 0.150 |
Why?
|
Neutropenia | 2 | 2016 | 891 | 0.150 |
Why?
|
Antisickling Agents | 2 | 2015 | 80 | 0.140 |
Why?
|
Infant, Newborn | 9 | 2018 | 25575 | 0.140 |
Why?
|
Platelet Transfusion | 1 | 2019 | 314 | 0.140 |
Why?
|
Immunoconjugates | 2 | 2014 | 897 | 0.140 |
Why?
|
Hindlimb | 1 | 2018 | 505 | 0.140 |
Why?
|
Risk Factors | 13 | 2018 | 72145 | 0.140 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 11472 | 0.140 |
Why?
|
Erythrocytes | 1 | 2005 | 2452 | 0.130 |
Why?
|
Age Factors | 7 | 2017 | 18355 | 0.130 |
Why?
|
Hydroxyurea | 2 | 2015 | 290 | 0.130 |
Why?
|
Platelet Membrane Glycoproteins | 1 | 2016 | 293 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2021 | 4438 | 0.130 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 222 | 0.130 |
Why?
|
Down Syndrome | 2 | 2014 | 880 | 0.130 |
Why?
|
Seasons | 1 | 2001 | 1492 | 0.130 |
Why?
|
Dyskeratosis Congenita | 1 | 2015 | 72 | 0.120 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39004 | 0.120 |
Why?
|
Blood Component Transfusion | 1 | 2015 | 142 | 0.120 |
Why?
|
Peroxidase | 1 | 2017 | 610 | 0.120 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 689 | 0.120 |
Why?
|
Donor Selection | 2 | 2013 | 201 | 0.120 |
Why?
|
Respiratory Tract Infections | 1 | 2001 | 959 | 0.110 |
Why?
|
Inflammation | 1 | 2013 | 10578 | 0.110 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2018 | 495 | 0.110 |
Why?
|
Blood Donors | 2 | 2012 | 355 | 0.110 |
Why?
|
Fanconi Anemia | 1 | 2015 | 319 | 0.110 |
Why?
|
Lymphocyte Activation | 3 | 2013 | 5519 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 264 | 0.100 |
Why?
|
Retrospective Studies | 14 | 2023 | 77098 | 0.100 |
Why?
|
Prognosis | 7 | 2021 | 29010 | 0.100 |
Why?
|
Genetic Diseases, Inborn | 1 | 2016 | 587 | 0.100 |
Why?
|
Receptors, Interleukin-2 | 1 | 2013 | 573 | 0.100 |
Why?
|
Immunocompromised Host | 1 | 2016 | 847 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2015 | 804 | 0.100 |
Why?
|
Diabetes Complications | 1 | 2018 | 1359 | 0.100 |
Why?
|
Neovascularization, Physiologic | 1 | 2018 | 1350 | 0.100 |
Why?
|
Leukocyte-Adhesion Deficiency Syndrome | 1 | 2010 | 21 | 0.100 |
Why?
|
Immunity, Mucosal | 1 | 2014 | 491 | 0.090 |
Why?
|
Gonadal Disorders | 1 | 2009 | 7 | 0.090 |
Why?
|
Disease Management | 2 | 2018 | 2450 | 0.090 |
Why?
|
Recurrence | 5 | 2022 | 8333 | 0.090 |
Why?
|
Disease Susceptibility | 1 | 2016 | 1780 | 0.090 |
Why?
|
Spleen | 1 | 2016 | 2359 | 0.090 |
Why?
|
Ischemia | 1 | 2018 | 1911 | 0.090 |
Why?
|
Survival Rate | 7 | 2013 | 12773 | 0.090 |
Why?
|
C-Reactive Protein | 1 | 2001 | 3766 | 0.080 |
Why?
|
Treatment Outcome | 14 | 2014 | 62966 | 0.080 |
Why?
|
Lung Diseases, Obstructive | 1 | 2009 | 316 | 0.080 |
Why?
|
Immunologic Memory | 1 | 2015 | 1348 | 0.080 |
Why?
|
beta-Thalassemia | 1 | 2010 | 225 | 0.080 |
Why?
|
Blood Transfusion | 1 | 2015 | 1296 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2021 | 3527 | 0.080 |
Why?
|
Odds Ratio | 2 | 2015 | 9846 | 0.080 |
Why?
|
Antineoplastic Agents | 3 | 2013 | 13655 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2007 | 647 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2013 | 12344 | 0.070 |
Why?
|
Sirolimus | 2 | 2014 | 1562 | 0.070 |
Why?
|
T-Lymphocyte Subsets | 1 | 2015 | 1837 | 0.070 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1811 | 0.070 |
Why?
|
Etoposide | 2 | 2006 | 637 | 0.070 |
Why?
|
Leukocytes | 1 | 2015 | 2039 | 0.070 |
Why?
|
Transplantation Chimera | 2 | 2009 | 612 | 0.070 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 2133 | 0.070 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2007 | 227 | 0.070 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2005 | 15 | 0.070 |
Why?
|
Colony-Stimulating Factors | 1 | 2006 | 216 | 0.070 |
Why?
|
Chronic Disease | 2 | 2017 | 9144 | 0.070 |
Why?
|
Anti-Infective Agents | 1 | 2013 | 971 | 0.070 |
Why?
|
Recovery of Function | 1 | 2016 | 2924 | 0.070 |
Why?
|
Central Nervous System Diseases | 1 | 2009 | 518 | 0.060 |
Why?
|
Multivariate Analysis | 3 | 2011 | 12242 | 0.060 |
Why?
|
Adrenal Cortex Hormones | 1 | 2014 | 1847 | 0.060 |
Why?
|
Cyclosporine | 2 | 2021 | 784 | 0.060 |
Why?
|
Growth | 1 | 2007 | 376 | 0.060 |
Why?
|
Creatinine | 1 | 2010 | 1916 | 0.060 |
Why?
|
Hemoglobinopathies | 1 | 2005 | 96 | 0.060 |
Why?
|
Pilot Projects | 2 | 2015 | 8297 | 0.060 |
Why?
|
Tacrolimus | 2 | 2021 | 741 | 0.060 |
Why?
|
Ovalbumin | 1 | 2005 | 719 | 0.060 |
Why?
|
Reference Values | 1 | 2011 | 4982 | 0.060 |
Why?
|
Chickens | 1 | 2005 | 865 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2017 | 21719 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2014 | 8621 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2013 | 3199 | 0.060 |
Why?
|
Middle Aged | 14 | 2021 | 213127 | 0.060 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2010 | 1675 | 0.050 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 623 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2011 | 6365 | 0.050 |
Why?
|
Forecasting | 1 | 2011 | 2948 | 0.050 |
Why?
|
Antigens, CD34 | 1 | 2003 | 657 | 0.050 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2536 | 0.050 |
Why?
|
Transplantation, Autologous | 2 | 2018 | 2123 | 0.050 |
Why?
|
Matched-Pair Analysis | 1 | 2001 | 288 | 0.050 |
Why?
|
Cross-Sectional Studies | 3 | 2016 | 24913 | 0.050 |
Why?
|
Macaca mulatta | 2 | 2021 | 2378 | 0.040 |
Why?
|
Risk Assessment | 3 | 2011 | 23320 | 0.040 |
Why?
|
Hematopoiesis | 1 | 2009 | 2066 | 0.040 |
Why?
|
Reoperation | 1 | 2009 | 4200 | 0.040 |
Why?
|
Cell Count | 1 | 2003 | 1831 | 0.040 |
Why?
|
Bone Marrow | 2 | 2007 | 2941 | 0.040 |
Why?
|
Kidney Transplantation | 1 | 2014 | 4246 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2001 | 425 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1040 | 0.040 |
Why?
|
Leukocyte Count | 2 | 2015 | 1583 | 0.040 |
Why?
|
Fibrinogen | 1 | 2001 | 894 | 0.040 |
Why?
|
Salmonella Food Poisoning | 1 | 1995 | 14 | 0.030 |
Why?
|
Health Status | 1 | 2009 | 4030 | 0.030 |
Why?
|
Frail Elderly | 1 | 2001 | 691 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 14720 | 0.030 |
Why?
|
Salmonella typhi | 1 | 1995 | 200 | 0.030 |
Why?
|
Methotrexate | 1 | 2021 | 1720 | 0.030 |
Why?
|
Typhoid Fever | 1 | 1995 | 196 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2017 | 651 | 0.030 |
Why?
|
Cohort Studies | 2 | 2011 | 40450 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2015 | 5975 | 0.030 |
Why?
|
World Health Organization | 1 | 2019 | 1317 | 0.030 |
Why?
|
Piperazines | 1 | 2004 | 2488 | 0.030 |
Why?
|
Cytogenetic Analysis | 1 | 2013 | 295 | 0.030 |
Why?
|
Emigration and Immigration | 1 | 1995 | 403 | 0.030 |
Why?
|
Time Factors | 3 | 2008 | 40054 | 0.030 |
Why?
|
Pyrimidines | 1 | 2004 | 2933 | 0.030 |
Why?
|
Carrier State | 1 | 1995 | 518 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 2016 | 2027 | 0.030 |
Why?
|
Phenotype | 2 | 2018 | 16331 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2006 | 9941 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2018 | 1376 | 0.020 |
Why?
|
HLA-DQ Antigens | 1 | 2010 | 210 | 0.020 |
Why?
|
International Agencies | 1 | 2010 | 240 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 228 | 0.020 |
Why?
|
Aged | 6 | 2021 | 162944 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 20928 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4187 | 0.020 |
Why?
|
Cell Lineage | 1 | 2018 | 2504 | 0.020 |
Why?
|
HLA-B Antigens | 1 | 2010 | 353 | 0.020 |
Why?
|
Chimerism | 1 | 2010 | 158 | 0.020 |
Why?
|
Transplantation | 1 | 2010 | 217 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 2010 | 644 | 0.020 |
Why?
|
Trans-Activators | 1 | 2018 | 2924 | 0.020 |
Why?
|
Prospective Studies | 2 | 2010 | 53187 | 0.020 |
Why?
|
Models, Genetic | 1 | 2018 | 3493 | 0.020 |
Why?
|
Autoantibodies | 1 | 2016 | 2036 | 0.020 |
Why?
|
Mesenchymal Stem Cells | 1 | 2018 | 1625 | 0.020 |
Why?
|
Animals | 4 | 2021 | 168561 | 0.020 |
Why?
|
Salvage Therapy | 1 | 2014 | 1269 | 0.020 |
Why?
|
Sex Factors | 1 | 2001 | 10392 | 0.020 |
Why?
|
Disease Progression | 1 | 2003 | 13256 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 1995 | 1768 | 0.020 |
Why?
|
Blood Platelets | 1 | 2016 | 2506 | 0.020 |
Why?
|
Genome, Human | 1 | 2018 | 4420 | 0.020 |
Why?
|
Registries | 2 | 2014 | 8077 | 0.020 |
Why?
|
Pediatrics | 1 | 2019 | 3462 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2017 | 4664 | 0.020 |
Why?
|
Haplotypes | 1 | 2010 | 2781 | 0.010 |
Why?
|
Chemoprevention | 1 | 2006 | 319 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2010 | 956 | 0.010 |
Why?
|
Melphalan | 1 | 2005 | 431 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7901 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2013 | 5062 | 0.010 |
Why?
|
Canada | 1 | 2008 | 2061 | 0.010 |
Why?
|
Mutation | 2 | 2018 | 29717 | 0.010 |
Why?
|
Genetic Variation | 1 | 2018 | 6540 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6534 | 0.010 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2004 | 403 | 0.010 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 902 | 0.010 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2004 | 462 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3585 | 0.010 |
Why?
|
Genomics | 1 | 2018 | 5692 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2018 | 19223 | 0.010 |
Why?
|
Europe | 1 | 2008 | 3339 | 0.010 |
Why?
|
Probability | 1 | 2007 | 2502 | 0.010 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 627 | 0.010 |
Why?
|
Body Height | 1 | 2007 | 1574 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 21821 | 0.010 |
Why?
|
Liver | 1 | 2016 | 7470 | 0.010 |
Why?
|
Blood Grouping and Crossmatching | 1 | 2000 | 106 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18006 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6931 | 0.010 |
Why?
|
United States | 2 | 2022 | 69693 | 0.010 |
Why?
|
Nuclear Family | 1 | 2000 | 318 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2013 | 11001 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2000 | 637 | 0.010 |
Why?
|
Benzamides | 1 | 2004 | 1378 | 0.010 |
Why?
|
Translocation, Genetic | 1 | 2004 | 1417 | 0.010 |
Why?
|
Mice | 1 | 2005 | 81045 | 0.010 |
Why?
|
Stomatitis | 1 | 2000 | 269 | 0.010 |
Why?
|
Weight Gain | 1 | 2007 | 2282 | 0.010 |
Why?
|
El Salvador | 1 | 1995 | 39 | 0.010 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2004 | 1581 | 0.010 |
Why?
|
Holidays | 1 | 1995 | 42 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2001 | 57683 | 0.010 |
Why?
|
Maryland | 1 | 1995 | 276 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 9185 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2010 | 10472 | 0.010 |
Why?
|
Neutrophils | 1 | 2007 | 3711 | 0.010 |
Why?
|
Length of Stay | 1 | 2007 | 6294 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 17400 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2014 | 15244 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15530 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2008 | 19862 | 0.010 |
Why?
|
Aging | 1 | 2007 | 8626 | 0.000 |
Why?
|
Anti-Bacterial Agents | 1 | 2006 | 7153 | 0.000 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2000 | 10943 | 0.000 |
Why?
|
Hospitalization | 1 | 2006 | 10232 | 0.000 |
Why?
|
Population Surveillance | 1 | 1995 | 2616 | 0.000 |
Why?
|
Risk | 1 | 1995 | 9679 | 0.000 |
Why?
|